Astria Therapeutics Inc (ATXS) - Total Assets
Based on the latest financial reports, Astria Therapeutics Inc (ATXS) holds total assets worth $271.87 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Astria Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Astria Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Astria Therapeutics Inc (ATXS) total market value for the company's overall valuation and market capitalisation.
Astria Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Astria Therapeutics Inc's total assets of $271.87 Million consist of 97.8% current assets and 2.3% non-current assets. Review ATXS total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Astria Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Astria Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Astria Therapeutics Inc's current assets represent 97.8% of total assets in 2024, an increase from 89.0% in 2012.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2024, down from 86.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Astria Therapeutics Inc Competitors by Total Assets
Key competitors of Astria Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Astria Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.78 | 22.38 | 7.25 |
| Quick Ratio | 10.78 | 22.38 | 7.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $230.03 Million | $336.14 Million | $39.94 Million |
Astria Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Astria Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.21 |
| Latest Market Cap to Assets Ratio | 2.10 |
| Asset Growth Rate (YoY) | 34.4% |
| Total Assets | $342.36 Million |
| Market Capitalization | $718.13 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Astria Therapeutics Inc's assets at a significant premium (2.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Astria Therapeutics Inc's assets grew by 34.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Astria Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Astria Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $342.36 Million | +34.44% |
| 2023-12-31 | $254.67 Million | +10.42% |
| 2022-12-31 | $230.63 Million | +80.87% |
| 2021-12-31 | $127.51 Million | +168.70% |
| 2020-12-31 | $47.46 Million | +13.59% |
| 2019-12-31 | $41.78 Million | +6.67% |
| 2018-12-31 | $39.17 Million | +118.86% |
| 2017-12-31 | $17.90 Million | -55.49% |
| 2016-12-31 | $40.21 Million | -37.39% |
| 2015-12-31 | $64.22 Million | +302.30% |
| 2014-12-31 | $15.96 Million | -48.51% |
| 2013-12-31 | $31.00 Million | +490904.12% |
| 2012-12-31 | $6.31K | -- |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more